Cryoport Inc

Insider Trading Arrangements and Policies

On March 15, 2024, Jerrell W. Shelton, our President and Chief Executive Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Shelton’s plan covers the potential sale of (i) up to 382,032 shares of our common stock to be acquired upon the exercise of stock options, and (ii) an undetermined number of shares of common stock pursuant to sell-to-cover transactions in order to cover the exercise price and holder’s tax liability associated with the exercise of up to 486,559 stock options during the term of such plan, with the specific amount of shares to be sold being dependent on the market price of the shares of our common stock at the time of such transactions. Transactions under Mr. Shelton’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Shelton’s plan will terminate on the earlier of December 15, 2024 or the date all shares subject to the plan have been sold.

On March 15, 2024, Ramkumar Mandalam, a member of our Board of Directors, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Dr. Mandalam’s plan covers the potential sale of up to 24,912 shares of our common stock to be acquired upon the exercise of stock options or settlement of restricted stock units. Transactions under Dr. Mandalam’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Dr. Mandalam’s plan will terminate on the earlier of December 15, 2024 or the date all shares subject to the plan have been sold.